Home > Animal Health & Nutrition > Veterinary Services > Dog Dewormers Market

Dog Dewormers Market Trends

Report ID: GMI11674
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Dog Dewormers Market Trends

The latest technological advancements in dog dewormers are playing a crucial role in driving the growth of the market. These innovations enhance efficacy, convenience, and safety, encouraging more pet owners to adopt regular deworming practices for their dogs.

Newer dewormers offer extended-release formulations that provide long-lasting protection, reducing the need for frequent dosing. For instance, injectable dewormers such as ProHeart 12 (Zoetis) offer protection against heartworms and intestinal parasites for up to 12 months with a single dose, improving compliance and convenience for pet owners.
Additionally, advances in combination therapies allow a single treatment to target multiple types of parasites. Products like Interceptor Plus (Elanco Animal Health) and NexGard Spectra (Boehringer Ingelheim Animal Health) protect against a broad spectrum of internal and external parasites, offering all-in-one protection with fewer medications, which simplifies parasite control for pet owners.
Moreover, modern injectable and topical dewormers feature improved delivery systems that enhance absorption and reduce side effects. These technologies ensure precise dosages and make administration easier, particularly for pets that struggle with oral medications. These technological advancements make dog deworming more effective, convenient, and safe, contributing to the growing demand and expansion of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The industry was valued at approximately USD 1.4 billion in 2023 and is projected to grow at a 9.5% CAGR from 2024 to 2032, driven by increased pet ownership and a rising focus on zoonotic diseases.

Tablets and chewable treats generated the highest revenue of USD 768.6 million in 2023. Their popularity stems from their convenience, ease of administration, and high compliance rates among pet owners.

In 2023, North America's market recorded USD 513.3 million in revenue and is anticipated to grow at a CAGR of 9.1% between 2024 and 2032. The high pet ownership rates in the U.S. and Canada drive this demand, as owners seek to keep their pets free from parasites.

Some of the prominent market participants include Bayer AG, Beaphar, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Durvet Animal Health Products, Elanco Animal Health Incorporated, Jurox Pty Limited, Merck & Co., Inc., Ourofino Animal Health, and PetIQ, LLC.